Zydus Cadila gets USFDA nod for antihistamine drug
The drug will be produced at the group's formulation manufacturing facility at the pharma SEZ in Ahmedabad, it added.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Cyproheptadine Hydrochloride tablets in the strength of 4 mg, Cadila Healthcare said in a BSE filing.
The drug will be produced at the group's formulation manufacturing facility at the pharma SEZ in Ahmedabad, it added.
The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), Cadila Healthcare said.
The tablets are used to relieve allergy symptoms such as hives, watery eyes, sneezing and itching eyes or nose, it added.
Shares of Cadila Healthcare were trading 2.78 per cent down at Rs 445.10 on BSE.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions